Journal
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
Volume 28, Issue 4, Pages 631-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2019.06.014
Keywords
Distal cholangiocarcinoma; Extrahepatic cholangiocarcinoma; Adjuvant therapy; Risk factors; Surgery
Ask authors/readers for more resources
Distal cholangiocarcinoma is a rare malignancy with a dismal prognosis. Because of its location and aggressive nature, patients often present with locally advanced or metastatic disease, and effective treatment options are limited. For patients with resectable disease, surgery is the only chance for cure, but achieving an R0 resection is paramount. Optimal adjuvant therapy in resectable disease remains under investigation. Randomized controlled trials investigating neoadjuvant therapy and its impact on resectability and long-term outcomes are needed to continue to improve the outcomes of patients with distal cholangiocarcinoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available